Gene Expression Profiles of Acute Exacerbations of Idiopathic Pulmonary Fibrosis
The molecular mechanisms underlying acute exacerbations of idiopathic pulmonary fibrosis (IPF) are poorly understood. We studied the global gene expression signature of acute exacerbations of IPF. To understand the gene expression patterns of acute exacerbations of IPF. RNA was extracted from 23 sta...
Saved in:
Published in | American journal of respiratory and critical care medicine Vol. 180; no. 2; pp. 167 - 175 |
---|---|
Main Authors | , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
New York, NY
Am Thoracic Soc
15.07.2009
American Thoracic Society |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The molecular mechanisms underlying acute exacerbations of idiopathic pulmonary fibrosis (IPF) are poorly understood. We studied the global gene expression signature of acute exacerbations of IPF.
To understand the gene expression patterns of acute exacerbations of IPF.
RNA was extracted from 23 stable IPF lungs, 8 IPF lungs with acute exacerbation (IPF-AEx), and 15 control lungs and used for hybridization on Agilent gene expression microarrays. Functional analysis of genes was performed with Spotfire and Genomica. Gene validations for MMP1, MMP7, AGER, DEFA1-3, COL1A2, and CCNA2 were performed by real-time quantitative reverse transcription-polymerase chain reaction. Immunohistochemistry and in situ terminal deoxynucleotidyltransferase dUTP nick end-labeling assays were performed on the same tissues used for the microarray. ELISA for alpha-defensins was performed on plasma from control subjects, patients with stable IPF, and patients with IPF-AEx.
Gene expression patterns in IPF-AEx and IPF samples were similar for the genes that distinguish IPF from control lungs. Five hundred and seventy-nine genes were differentially expressed (false discovery rate < 5%) between stable IPF and IPF-AEx. Functional analysis of these genes did not indicate any evidence of an infectious or overwhelming inflammatory etiology. CCNA2 and alpha-defensins were among the most up-regulated genes. CCNA2 and alpha-defensin protein levels were also higher and localized to the epithelium of IPF-AEx, where widespread apoptosis was also detected. alpha-Defensin protein levels were increased in the peripheral blood of patients with IPF-AEx.
Our results indicate that IPF-AEx is characterized by enhanced epithelial injury and proliferation, as reflected by increases in CCNA2 and alpha-defensins and apoptosis of epithelium. The concomitant increase in alpha-defensins in the peripheral blood and lungs may suggest their use as biomarkers for this disorder. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 This article has an online supplement, which is accessible from this issue's table of contents at www.atsjournals.org Correspondence and requests for reprints should be addressed to Naftali Kaminski, M.D., University of Pittsburgh Medical Center, NW 628 MUH, 3459 5th Avenue, Pittsburgh, PA 15261. E-mail: kaminskin@upmc.edu (Naftali Kaminski, M.D.); dskim@amc.seoul.kr (Dong Soon Kim, M.D.). Supported by NIH grants HL073745, HL0894932, and HL095397 and by the Dorothy P. and Richard P. Simmons Endowed Chair for Interstitial Lung Disease. Originally Published in Press as DOI: 10.1164/rccm.200810-1596OC on April 16, 2009 Conflict of Interest Statement: K.K. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. K.F.G. is an inventor on a patent application of the use of peripheral blood proteins as biomarkers. K.O.L. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. T.J.R. is an inventor on a patent application of the use of peripheral blood proteins as biomarkers. Y.Z. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. R.D. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. M.B. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. S.G. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. S.A.Y. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. J.W.S. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. D.S.K. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. N.K. is a primary investigator on two industry investigator initiated grants, one from Biogen Idec for $674,000 and the other from Centocor for $250,000. N.K. is an inventor on a patent application for the use of peripheral blood proteins as biomarkers. |
ISSN: | 1073-449X 1535-4970 1535-4970 |
DOI: | 10.1164/rccm.200810-1596OC |